Drug Profile

KPL 1161

Alternative Names: KPL-1161

Latest Information Update: 09 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kiniksa Pharmaceuticals
Class Cardiovascular therapies; Immunoglobulin Fc fragments; Monoclonal antibodies
Mechanism of Action Interleukin 1 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Cardiovascular disorders

Most Recent Events

25 Feb 2026 Kiniksa Pharmaceuticals has patents pending for KPL 1161 before February 2026
24 Feb 2026 Kiniksa Pharmaceuticals plans a phase I first-in-human clinical trial in healthy volunteers (SC) by the end of 2026
25 Feb 2025 Preclinical trials in Cardiovascular disorders in USA (SC) before February 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com